Entasis Therapeutics Holdings Inc (ETTX) Stock Price & Overview
NASDAQ:ETTX • US2936141033
Current stock price
The current stock price of ETTX is 2.19 null. Today ETTX is down by -0.45%. In the past year, price decreased by -12.05%.
ETTX Key Statistics
- Market Cap
- 104.795M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.12
- Dividend Yield
- N/A
ETTX Stock Performance
ETTX Stock Chart
ETTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ETTX. When comparing the yearly performance of all stocks, ETTX is one of the better performing stocks in the market, outperforming 90.67% of all stocks.
ETTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ETTX. ETTX may be in some trouble as it scores bad on both profitability and health.
ETTX Earnings
ETTX Forecast & Estimates
8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.
ETTX Groups
Sector & Classification
ETTX Financial Highlights
Over the last trailing twelve months ETTX reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 28.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.26% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ETTX Ownership
ETTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 365.196B | ||
| AMGN | AMGEN INC | 15.37 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.1 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.62 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ETTX
Company Profile
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Company Info
IPO: 2018-09-26
Entasis Therapeutics Holdings Inc
35 Gatehouse Drive
Waltham MASSACHUSETTS 02451 US
CEO: Manoussos Perros
Employees: 51
Phone: 17818100120.0
Entasis Therapeutics Holdings Inc / ETTX FAQ
What does Entasis Therapeutics Holdings Inc do?
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Can you provide the latest stock price for Entasis Therapeutics Holdings Inc?
The current stock price of ETTX is 2.19 null. The price decreased by -0.45% in the last trading session.
Does ETTX stock pay dividends?
ETTX does not pay a dividend.
How is the ChartMill rating for Entasis Therapeutics Holdings Inc?
ETTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does Entasis Therapeutics Holdings Inc belong to?
Entasis Therapeutics Holdings Inc (ETTX) operates in the Health Care sector and the Biotechnology industry.
What is Entasis Therapeutics Holdings Inc worth?
Entasis Therapeutics Holdings Inc (ETTX) has a market capitalization of 104.80M null. This makes ETTX a Micro Cap stock.
Can you provide the upcoming earnings date for Entasis Therapeutics Holdings Inc?
Entasis Therapeutics Holdings Inc (ETTX) will report earnings on 2022-08-09.